Analyst Consensus ?
ConsensusHold25 ratings
Bullish728.0%
Neutral1664.0%
Bearish28.0%
Avantor, Inc. · AVTR · FY2025 Q2 · Calendar Q3 2025
Avantor cuts 2025 outlook as pricing and bioprocessing weigh on results
Avantor’s Q2 account is mixed but skewed cautious: contract extensions, digital initiatives and cost savings offer potential offsets, while pricing pressure and customer- and facility-specific bioprocessing disruptions are weighing on growth and margins. The lower full-year outlook makes evidence of a sustained recovery important to the investment case.
Reported Before market openNYSEHealthcare
$10.58B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.24
Consensus $0.25
EPS surprise
-4.0%
Reported versus consensus
Reported revenue
$1.68B
Consensus $1.65B
Revenue surprise
+2.3%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-15.5%
Event window
SPY move
-1.6%
Same window
Abnormal move
-13.8%
Stock minus SPY
Volume
5.1×
Versus trailing sessions
Subsequent drift
+18.6%
Up to 20 sessions
AVTRSPY benchmark
Ask FN2 about AVTR FY2025 Q2
Transcript, numbers and history already loaded
Why did AVTR fall 15.5% after missing EPS estimates in FY2025 Q2?What changed in AVTR's guidance and outlook in FY2025 Q2?Give me the bull and bear case for AVTR after FY2025 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with Q1, management lowered its full-year organic revenue growth outlook to -2% to 0% and provided a 16.5%-17% adjusted EBITDA margin outlook. Q2 revenue was flat year over year and adjusted EPS was $0.24. The call analysis attributes pressure to Lab Solutions pricing and bioprocessing disruptions, while highlighting more than $100 million in share-gain contract extensions.
Guidance delta
Lowered: management projected full-year organic revenue growth of -2% to 0%, adjusted EBITDA margin of 16.5%-17%, adjusted EPS of $0.94-$0.98 and free cash flow of $550-$600 million. The prior-quarter analysis says revenue guidance was lowered while EPS was unchanged; the supplied analysis does not provide a prior range for every metric.
Key takeaways
- Q2 revenue was flat year over year; adjusted EPS was $0.24 and adjusted EBITDA margin was 16.6%.
- Lab Solutions contract extensions could contribute more than $100 million in share gains, but pricing and mix pressure weighed on margins.
- Bioprocessing lagged amid extended facility maintenance and customer-specific setbacks, including regulatory and clinical developments described in the call analysis.
- Management emphasized digital buying and pricing tools and a cost-transformation program targeting $400 million of savings.
Management priorities
- Deploy Avantor Navigator and a unified digital buying platform across channels.
- Continue pricing-tool rollout to improve agility and conversion.
- Accelerate cost transformation toward the stated $400 million savings target.
- Increase field-sales intensity and optimize the bioprocessing supply chain; expand offerings in silicones, biosimilars and antibody-drug conjugates.
Follow AVTR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$15.79Current
$7Low
$20.05Average
$50High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 3, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Stifel | Hold | Hold | Maintain | Oct 29, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Oct 29, 2026 |
| Barclays | Underweight | Underweight | Maintain | Oct 29, 2026 |
| Baird | Outperform | Outperform | Maintain | Oct 29, 2026 |
| TD Cowen | Hold | Hold | Maintain | Oct 13, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Oct 13, 2026 |
| UBS | Neutral | Neutral | Maintain | Sep 9, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jul 30, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Jul 30, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Jul 8, 2026 |
| Jefferies | Underperform | Hold | Downgrade | Dec 17, 2025 |
| JP Morgan | Neutral | Overweight | Downgrade | Oct 30, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Oct 16, 2025 |
| Goldman Sachs | Neutral | Buy | Downgrade | Apr 29, 2025 |
| Deutsche Bank | Hold | Hold | Maintain | Apr 18, 2024 |
| William Blair | Market Perform | Outperform | Downgrade | Jul 31, 2023 |
| Credit Suisse | Neutral | Neutral | Maintain | Jul 31, 2023 |
| B of A Securities | Buy | Buy | Maintain | Jul 31, 2023 |
| Keybanc | Overweight | Overweight | Maintain | Sep 15, 2022 |
| Cowen & Co. | Market Perform | Outperform | Downgrade | Sep 14, 2022 |
| Cleveland Research | Neutral | Buy | Downgrade | Sep 9, 2022 |
| Piper Sandler | Overweight | Neutral | Upgrade | Aug 2, 2021 |
| Stifel Nicolaus | Hold | Hold | Maintain | Nov 15, 2019 |
| Janney Capital | Buy | Buy | Maintain | Jun 14, 2019 |
| Piper Jaffray | Neutral | Neutral | Maintain | Jun 11, 2019 |
Named analyst price targets
Upside is calculated against the persisted current price $15.79. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Deutsche Bank | Analyst unavailable | $17 | $16.46 | +7.7% | Oct 29, 2026 |
| Robert W. Baird | Analyst unavailable | $18 | $16.69 | +14.0% | Oct 29, 2026 |
| Barclays | Analyst unavailable | $16 | $16.69 | +1.3% | Oct 29, 2026 |
| Evercore ISI | Analyst unavailable | $17 | $16.69 | +7.7% | Oct 28, 2026 |
| RBC Capital | Dan Leonard | $17 | $16.69 | +7.7% | Oct 28, 2026 |
| UBS | Doug Schenkel | $16 | $15.25 | +1.3% | Sep 9, 2026 |
| Morgan Stanley | Analyst unavailable | $14 | $13.66 | -11.3% | Jul 30, 2026 |
| RBC Capital | Dan Leonard | $14 | $13.98 | -11.3% | Jul 30, 2026 |
| Deutsche Bank | Analyst unavailable | $13 | $14.06 | -17.7% | Jul 30, 2026 |
| Jefferies | Analyst unavailable | $13 | $14.38 | -17.7% | Jul 29, 2026 |
| Evercore ISI | Analyst unavailable | $10.5 | $10.4 | -33.5% | Jul 6, 2026 |
| Bernstein | Analyst unavailable | $10.5 | $10.08 | -33.5% | Jun 26, 2026 |
| UBS | Analyst unavailable | $8 | $9.43 | -49.3% | Jun 24, 2026 |
| Wolfe Research | Analyst unavailable | $7 | $9.19 | -55.7% | Jun 1, 2026 |
| RBC Capital | Analyst unavailable | $9 | $7.94 | -43.0% | May 14, 2026 |
| Barclays | Analyst unavailable | $7 | $8.18 | -55.7% | Apr 14, 2026 |
| Morgan Stanley | Analyst unavailable | $10 | $9.38 | -36.7% | Feb 13, 2026 |
| UBS | Dan Leonard | $10.5 | $9.34 | -33.5% | Feb 12, 2026 |
| Stifel Nicolaus | Analyst unavailable | $10 | $9.24 | -36.7% | Feb 12, 2026 |
| Jefferies | Tycho Peterson | $8 | $9.24 | -49.3% | Feb 12, 2026 |
| Barclays | Analyst unavailable | $9 | $9.64 | -43.0% | Feb 12, 2026 |
| Robert W. Baird | Analyst unavailable | $11 | $9.64 | -30.3% | Feb 12, 2026 |
| Evercore ISI | Vijay Kumar | $10 | $9.32 | -36.7% | Feb 11, 2026 |
| Evercore ISI | Analyst unavailable | $12 | $11.46 | -24.0% | Jan 5, 2026 |
| Jefferies | Tycho Peterson | $9 | $11.2 | -43.0% | Dec 17, 2025 |
| Barclays | Luke Sergott | $12 | $11.58 | -24.0% | Oct 30, 2025 |
| UBS | Analyst unavailable | $12 | $11.58 | -24.0% | Oct 30, 2025 |
| Barclays | Luke Sergott | $15 | $13.67 | -5.0% | Oct 2, 2025 |
| Stifel Nicolaus | Analyst unavailable | $12 | $11.3 | -24.0% | Aug 4, 2025 |
| Raymond James | Analyst unavailable | $14 | $11.3 | -11.3% | Aug 4, 2025 |
| Robert W. Baird | Analyst unavailable | $17 | $12.49 | +7.7% | Apr 28, 2025 |
| Morgan Stanley | Tejas Savant | $15 | $12.93 | -5.0% | Apr 28, 2025 |
| Barclays | Luke Sergott | $26 | $21.87 | +64.7% | Feb 3, 2025 |
| Bernstein | Eve Burstein | $24.5 | $21.66 | +55.2% | Jan 10, 2025 |
| Evercore ISI | Vijay Kumar | $26 | $21.2 | +64.7% | Jan 2, 2025 |
| Robert W. Baird | Catherine Schulte | $26 | $22.56 | +64.7% | Oct 28, 2024 |
| Morgan Stanley | Tejas Savant | $28 | $24.4 | +77.3% | Oct 21, 2024 |
| Robert W. Baird | Catherine Schulte | $27 | $26.02 | +71.0% | Jul 29, 2024 |
| Evercore ISI | Vijay Kumar | $27.5 | $25.6 | +74.2% | Jul 26, 2024 |
| Evercore ISI | Vijay Kumar | $27 | $20.77 | +71.0% | Jul 2, 2024 |
| Jefferies | Tycho Peterson | $28 | $24.08 | +77.3% | Jun 3, 2024 |
| Deutsche Bank | Justin Bowers | $25 | $24.38 | +58.3% | Apr 18, 2024 |
| Raymond James | Andrew Cooper | $30 | $23.05 | +90.0% | Feb 5, 2023 |
| Raymond James | Andrew Cooper | $36 | $28.34 | +128.0% | Aug 9, 2022 |
| Robert W. Baird | Catherine Schulte | $34 | $28.34 | +115.3% | Aug 8, 2022 |
| Barclays | Luke Sergott | $33 | $28.67 | +109.0% | Aug 4, 2022 |
| Wells Fargo | Analyst unavailable | $33 | $29.95 | +109.0% | Apr 25, 2022 |
| Stifel Nicolaus | Daniel Arias | $46 | $42.33 | +191.3% | Sep 10, 2021 |
| Credit Suisse | Katie Tryhane | $50 | $42.33 | +216.7% | Sep 10, 2021 |
| Guggenheim | Sandy Draper | $45 | $37.6 | +185.0% | Aug 2, 2021 |
| Morgan Stanley | Tejas Savant | $44 | $37.6 | +178.7% | Aug 2, 2021 |
| Goldman Sachs | Matthew Sykes | $40 | $31.3 | +153.3% | Jun 4, 2021 |
Track every rating change on AVTR the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAvantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample…
Historical context
All AVTR earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| PHG Koninklijke Philips N.V. | FY2026 Q3 · Calendar Q4 2026 | — | +4.8% | Philips Q3: order momentum and margins improve; outlook held |
| VRTX Vertex Pharmaceuticals Incorporated | FY2026 Q3 · Calendar Q4 2026 | -1.2% | -1.0% | Vertex lifts 2026 outlook as CF franchise and newer products support growth |
| JAZZ Jazz Pharmaceuticals plc | FY2026 Q3 · Calendar Q4 2026 | +4.2% | -0.7% | Jazz lifts 2026 revenue outlook as Ziihera launch adds momentum |
| BMRN BioMarin Pharmaceutical Inc. | FY2026 Q3 · Calendar Q4 2026 | +376.0% | -1.8% | BioMarin’s Q3 growth meets a lower full-year outlook |
| IDXX IDEXX Laboratories, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.2% | +21.8% | IDEXX Raises FY2026 Outlook on Diagnostics and Software Growth |
| NBIX Neurocrine Biosciences, Inc. | FY2026 Q3 · Calendar Q4 2026 | +72.3% | -0.5% | Neurocrine Raises INGREZZA Outlook as Core Products Grow |
Latest beats and misses
Who reports nextBeat on EPS
- TSEMFY2026 Q3 · November 2, 2026+7.5% EPS-6.7% move
- CLXFY2027 Q1 · November 2, 2026+44.9% EPS+2.2% move
- AAPLFY2026 Q4 · November 2, 2026+3.0% EPS-1.8% move
- PLTRFY2026 Q3 · November 2, 2026+8.3% EPS-3.1% move
- ETRFY2026 Q3 · November 2, 2026+14.5% EPS-0.2% move
- OFY2026 Q3 · November 2, 2026+5.7% EPS+1.1% move
Missed on EPS
- VRTXFY2026 Q3 · November 2, 2026-1.2% EPS-1.0% move
- PEGFY2026 Q3 · November 2, 2026-3.4% EPS+0.1% move
- RYAAYFY2027 Q2 · November 2, 2026-0.3% EPS+2.9% move
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
Get the AVTR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-03T13:20:48.346062+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T13:20:48.343203+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.